In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Penhaligon’s boutiques in Saks

This article was originally published in The Rose Sheet

Executive Summary

Penhaligon's parent company Cradle Holdings enters agreement with Saks Fifth Avenue to open six Penhaligon's outposts within Saks stores in the fall, retailer announces. Saks will open additional Penhaligon's boutiques over next several years, and will be exclusive point of distribution for specialty beauty brand outside of free-standing Penhaligon's stores. Cradle Holdings acquired Penhaligon's and Erno Laszlo in February (1"The Rose Sheet" Feb. 18, 2002, p. 7)...

You may also be interested in...



Penhaligon’s Owner Cradle Holdings Initiates U.S. Expansion

The specialty UK beauty brand Penhaligon's will undergo its first major U.S. expansion under Cradle Holdings, a new cosmetics business entity formed by private equity firm Fox Paine to "acquire and nurture promising prestige beauty companies.

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel